DBVT · DBV Technologies S.A.
Market Cap
$753.87M
Shares
62.85M
Volume · Sep 30
400.95K
Avg daily vol (3M)
309.19K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.76
Open$11.72
Day$11.72–12.21
52W close$10.00–24.54
Avg vol 30d294K
Short int1.4M · 2.2% float · 3.3d
Short vol78%
Last earningsJul 16, 2026
DataJan 2020–Sep 2026
Filing10-Q · Jul 16
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 5 wks
filed Jul 16, 2026
call held Jul 16, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.94M
Trailing 12 months
Net income (TTM)
−$175.95M
Trailing 12 months
Revenue growth YoY
-53.3%
Year over year
Operating margin
-3,603.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-21.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+222.4%
Year over year · more shares
Price change (1Y)
+26.3%
Trailing year
Short interest
2.2%
Latest settlement · 3.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−34%
below
Price vs 50-day avg
−12%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
12%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−12%
trailing
6-month return
−45%
trailing
YTD return
−39%
this year
Relative strength
−57%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $18 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +17 funds added
Insider flow
Distributing
Net -$1.3K over 90 days · 100% sells
Short interest
Falling
2.15% of float · ▼ -14.6% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
78 holders — near 3-yr high, broad support
Squeeze score
42
elevated · 0–100
Fundamentals
Revenue growth
+36%
Y/Y
EPS growth
+10%
Y/Y
Free cash flow
$-121.7M
Balance sheet
$191.8M
net cash
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−34%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
12%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $13 › 200d $18 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +17 funds added
Insider flow
Distributing
Net -$1.3K over 90 days · 100% sells
Short interest
Falling
2.15% of float · ▼ -14.6% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
78 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $10
Now $12 · 12%
Range high $25
vs 200-day avg -34%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DBVT
this stock
DBV Technologies S.A.
|
$753.87M | -38.7% | +35.8% | — | 2.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DBVT | -3.4% | -12.4% | -45.1% | -14.9% | -38.7% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -2.7% | -12.5% | -57.2% | -14.3% | -50.5% |